C-myc oncoprotein expression and gene amplification in apocrine metaplasia and apocrine change within sclerosing adenosis of the breast

Breast

Volumn 11, Issue 6, 2002, Pages 466-472

  Selim, Abdel Ghani A ^a   El Ayat, Ghada ^a   Naase, Mahmoud ^a   Wells, Clive A ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN;

ADULT; AGED; APOCRINE GLAND; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GRADING; CLINICAL ARTICLE; CONTROLLED STUDY; DNA PROBE; FIBROCYSTIC BREAST DISEASE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENETIC ANALYSIS; GENETIC DISORDER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; SWEAT GLAND DISEASE; TISSUE SECTION;

EID: 0036915924     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1054/brst.2002.0474     Document Type: Article

References (49)

1. Evan GI, Wyllie AH, Gilbert CS et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992; 69: 1-20.
2. Meyers SL, O'Brien MT, Smith T et al. Analysis of the int-1, int-2, c-myc, and neu oncogenes in human breast carcinomas. Cancer Res 1990; 50: 5911-5918.
3. Berns EM, Klijn JG, van Putten et al. C-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res 1992; 1: 1107-1113.
4. Pietilainen T, Lipponen P, Aaltomaa S et al. Expression of c-myc proteins in breast cancer as related to established prognostic factors and survival. Anticancer Res 1995; 15: 959-964.
5. Rosai J. Ackerman's Surgical Pathology, 8th Edition. New York: Mosby-Year Book, 1996; 1565-1659.
6. Page DL, Vander Zwaag R, Rogers LW et al. Relation between component parts of fibrocystic disease complex and breast cancer. J Natl Cancer Inst 1978, 61: 1055-1063.
7. Tavassoli FA, Norris HJ. Intraductal apocrine carcinoma: a clinicopathological study of 37 cases. Mod Pathol 1994; 7: 813-818.
8. Haagensen Jr DE Is cystic disease related to breast cancer? Am J Surg Pathol 1991; 15: 687-694.
9. Harrington E, Lesnik G. The association between gross cysts of the breast and breast cancer. Breast 1980; 7: 13-17.
10. Roberts MM, Jones V, Elton RA et al. Risk of breast cancer in women with history of benign disease of the breast. Br Med J 1984; 288: 275-278.
11. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative disease. N Engl J Med 1985; 312:146-151.
12. Page DL, Dupont WD, Jensen RA. Papillary apocrine change of the breast: association with atypical hyperplasia and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 1996; 5: 29-32.
13. Wells CA, McGregor IL, Makunura CN et al. Apocrine adenosis: a precursor of aggressive breast disease. J Clin Pathol 1995; 48: 737-742.
14. Seidman JD, Ashton M, Lefkowitz M. Atypical apocrine adenosis of the breast: clinicopathological study of 37 patients with 8.7-year follow up. Cancer 1996; 77: 2529-2537.
15. Izuo M, Okagaki T, Richart R et al. DNA content in 'apocrine metaplasia' of fibrocystic disease of the breast. Cancer 1971; 27: 643-650.
16. Vasiu R, Olinici CD. DNA nuclear content of apocrine cells in fibrocystic mastopathy and breast cancer. Morphol Embryol 1990; 36: 43-47.
17. Jones C, Damiani S, Wells D et al. Molecular cytogenetic comparison of apocrine hyperplasia and apocrine carcinoma of the breast. Am J Pathol. 2001; 158: 207-214.
18. Pauletti G, Godolphin W, Press MF et al. Detection and quantitation of HER-2/neu gene amplification in human breast cancer in archival material using fluorescence in situ hybridisation. Oncogene 1996; 13: 63-72.
19. Persons DL, Borelli KA, Hsu PH. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridisation. Mod Pathol 1997; 10: 720-727.
20. Visscher DW, Wallis T, Awussah S et al. Evaluation of MYC and Chromosome 8 copy number in breast carcinoma by interphase cytogenetics. Genes Chromosomes Cancer 1997; 18: 1-7.
21. Hsu S-M, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immmunoperoxidase techniques: a comparison between ABC and unlabelled antibody (PAP) procedures. J Histochem Cytochem 1981; 29: 577-580.
22. Norton AJ, Jordan S, Yeomans P. Brief, high temperature heat denaturation (pressure cooking): a simple and effective method of antigen retrieval for routinely processed tissues. J Pathol 1994; 173: 371-379.
23. Dekken HV, Bosman FT, Teijgeman R et al. Identification of numerical chromosome aberration in archival tumours by in situ hybridization in routine paraffin sections: evaluation of 23 phaeochromocytomas. J Pathol 1993; 171: 161-171.
24. Harrison M, Magee HM, O'Loughin J et al. Chromosome 1 aneusomy, identified by interphase cytogenetics, in mammographically detected ductal carcinoma in situ of the breast. J Pathol 1995, 175: 303-309.
25. Micale MA, Visscher W, Gulino SE et al. Chromosomal aneuploidy in proliferative breast disease. Hum Pathol 1994; 25: 29-35.
26. Visscher DW, Wallis TL, Crissman JD. Evaluation of chromosome aneuoploidy in tissue sections of preinvasive breast carcinoma using interphase cytogenetics. Cancer 1996; 77: 315-320.
27. Wellings SR, Jensen HM, Marcum RG. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst 1975; 55: 231-243.
28. Wellings SR, Alpers CE. Apocrine cystic metaplasia: subgross pathology and prevalence in cancer associated versus random autopsy breasts. Hum Pathol 1987; 18: 381-386.
29. Ness JC, Sedghinasab M, Moe RE et al. Identification of multiple proliferative growth factors in breast cyst fluid. Am J Surg 1993; 166: 237-243.
30. Bruzzi P, Dogliotti L, Naldoni C et al. Cohort study of association of risk of breast cancer with cyst type in women with gross cystic disease of the breast. BMJ 1997; 314: 925-928.
31. Haagensen CD. Apocrine epithelium. In: Diseases of the Breast, 3rd Edition. Philadelphia: W.B. Saunders, 1986; 82-101.
32. Papamichalis G, Francia K, Karachaliou FE et al. Expression of the c-myc oncoprotein in human metaplastic epithelial cells of fibrocystic disease. Anticancer Res 1988; 8: 1217-1222.
33. Agnantis NJ, Mahera H, Maounis N et al. Immunohistochemical study of ras and myc oncoproteins in apocrine breast lesions with and without papillomatosis. Eur J Gynaecol Oncol 1992; 13: 309-315.
34. McCann A, Johnston PA, Dervan PA et al. c-erbB2 oncoprotein expression in malignant and non-malignant breast tissue. Int J Med Sci 1989; 158: 137-140.
35. Spandidos DA, Anderson MLM. A study of the mechanism of carcinogenesis by gene transfer of oncogenes into mammalian cells. Mutat Res 1987; 185: 271-291.
36. Wyllie AH, Rose KA, Morris RG et al. Rodent fibroblast tumours expressing human myc and ras genes: growth, metastasis and endogenous oncogene expression. Br J Cancer 1987; 56: 251-259.
37. Boise LH, Gottschalk AR, Quintans J et al. Bcl-2 and Bcl-2 related proteins in apoptosis regulation. Curr Top Microbiol Immunol 1995, 200: 107-121.
38. Cummings MC, Winterford CM, Walker NI. Apoptosis. Am J Surg Pathol 1997; 21: 88-101.
39. Wolman SR, Pauley RJ, Mohamed AN et al. Genetic markers as prognostic indicators in breast cancer. Cancer 1992; 70: 1765-1774.
40. Nicolson GL. Tumour cell instability, diversification, and progression to the metastatic phenotype: from oncogene to oncofetal expression. Cancer Res 1987; 47: 1473-1487.
41. Emmerich P, Jauch A, Hofmann MC et al. Interphase cytogenetics in paraffin embedded sections from human testicular germ cell tumour xenografts and in corresponding cultured cells. Lab Invest 1989; 61: 235-242.
42. Edwards PAW, Ward JL, Bradbury JM. Alteration of morphogenesis by the v-myc oncogene in transplants of mouse mammary gland. Oncogene 1988; 2: 407-412.
43. Liao DJ, Dickson RB. C-myc in breast cancer. Endocr Relat Cancer 2000; 7: 143-164.
44. Deming SL, Nss SJ, Dickson RB, Trock BJ. C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br J Cancer 2000; 83: 1688-1695.
45. Escot C, Theillet C, Lidereau R et al. Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. Proc Natl Acad Sci USA 1986; 83: 4834-4838.
46. Locker AP, Dowle CS, Ellis IO et al. C-myc oncogene product expression and prognosis in operable breast cancer. Br J Cancer 1989; 60: 669-672.
47. Walker RA, Senior PV, Jones JL et al. An immunohistochemical and in situ hybridisation study of c-myc and c-erbB-2 expression in primary breast tumours. J Pathol 1989; 158: 97-105.
48. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
49. Coombs LM, Pigott DA, Sweeney E et al. Amplification and overexpression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer 1991; 62: 601-608.